| # | Drug | Count |
|---|---|---|
| 0 | PREDNISONE | 100 |
| 1 | TACROLIMUS | 79 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 73 |
| 3 | TACROLIMUS OINTMENT 0.1% | 73 |
| 4 | MYCOPHENOLATE MOFETIL | 66 |
| 5 | METHYLPREDNISOLONE | 55 |
| 6 | DEXAMETHASONE | 45 |
| 7 | DEXAMETHASONE 1.5 MG | 45 |
| 8 | VANCOMYCIN | 40 |
| 9 | CYCLOPHOSPHAMIDE | 39 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEFTOLOZANE AND TAZOBACTAM | 7 | 0.0071 |
| 1 | INOTUZUMAB OZOGAMICIN | 12 | 0.0040 |
| 2 | DEXCHLORPHENIRAMINE MALEATE | 3 | 0.0030 |
| 3 | DEFEROXAMINE MESYLATE | 3 | 0.0014 |
| 4 | BARICITINIB | 4 | 0.0013 |
| 5 | CEFEPIME HYDROCHLORIDE | 20 | 0.0012 |
| 6 | ALEMTUZUMAB | 22 | 0.0011 |
| 7 | VALGANCICLOVIR | 21 | 0.0011 |
| 8 | VORICONAZOLE | 32 | 0.0010 |
| 9 | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | 28 | 0.0010 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 212 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 86 |
| 2 | Azole Antifungal [EPC] | 46 |
| 3 | Glycopeptide Antibacterial [EPC] | 45 |
| 4 | Alkylating Drug [EPC] | 43 |
| 5 | Benzodiazepine [EPC] | 38 |
| 6 | CD20-directed Cytolytic Antibody [EPC] | 36 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 36 |
| 8 | Tumor Necrosis Factor Blocker [EPC] | 36 |
| 9 | Proton Pump Inhibitor [EPC] | 33 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 3 | 0.0044 |
| 1 | CD22-directed Immunoconjugate [EPC] | 12 | 0.0040 |
| 2 | CD52-directed Cytolytic Antibody [EPC] | 22 | 0.0011 |
| 3 | Lipid-based Polyene Antifungal [EPC] | 13 | 0.0010 |
| 4 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 22 | 0.0010 |
| 5 | Asparagine-specific Enzyme [EPC] | 12 | 0.0009 |
| 6 | Surfactant [EPC] | 1 | 0.0009 |
| 7 | Oxazolidinone Antibacterial [EPC] | 26 | 0.0009 |
| 8 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 11 | 0.0008 |
| 9 | Penem Antibacterial [EPC] | 28 | 0.0008 |